CN105395553A - Pharmaceutical composition for osteoarticular disease rehabilitation - Google Patents
Pharmaceutical composition for osteoarticular disease rehabilitation Download PDFInfo
- Publication number
- CN105395553A CN105395553A CN201510901800.5A CN201510901800A CN105395553A CN 105395553 A CN105395553 A CN 105395553A CN 201510901800 A CN201510901800 A CN 201510901800A CN 105395553 A CN105395553 A CN 105395553A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- joint disease
- treatment
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention relates to a pharmaceutical composition for treatment of osteoarticular diseases. The pharmaceutical composition includes an effective dose of a compound and a pharmaceutically acceptable carrier, and the compound has a structure shown as the specification. The compound involved in the invention has significant effect on osteoarticular diseases, and can be developed into clinically effective new pharmaceutical compositions.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for joint disease rehabilitation.
Background technology
Joint disease comprises hyperplastic osteoarthritis, degenerative joint disease, senile arthritis, hypertrophiarthritis, osteoarthritis.Its pathogeny is that degeneration, degeneration appear in the soft tissue such as cartilage, intervertebral disc, ligament forming joint, and joint margins forms bony spur or occurs the changes such as synovial membrane thickens, thus osteoclasia occurs, and causes insecondary hyperosteogeny and causes joint deformity.Joint disease is comparatively common, clinical manifestation be swollen joint, bitterly, hydrops, stiff, hypertrophy, bony spur, patient activity is limited, agonizing, many Drug therapys are generally relief of symptoms, are difficult to cure, and very easily repeatedly, serious threat the quality of life of people with healthy.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of joint disease.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of joint disease, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of joint disease, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment joint disease, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or diluent.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its compositions.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, antiseptic (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, antiseptic, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington ' sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the Be very effective of joint disease, can be developed to pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Experimental example
The structural formula of target compound is:
Osteoarthritis is the coefficient result of mechanics and biological factor, thinks that IgG2 α raises at present relevant with the order of severity of the course of disease and disease.IgG2 alpha levels is higher, and osteoarthritis is more serious.
Knee osteoarthritis model and administration
Cleaning grade (SPF) male Wistar rat (Mus 5-6 in age month weight 170.0 ± 20.5) is divided into 4 groups: Normal group (Normalcontrolgroup, NC), model control group (Modelcontrolgroup, MC), glucosamine matched group (Glucosaminecontrolgroup, GS), target compound group.Often organize 10.Except Normal group, respectively organize the Cys aqueous solution of right knee joint injection 4 % by weight Papain enzyme aqueous solution 10 μ L and 0.03mol/L of rat to all the other, and strengthened respectively at the 3rd, 7 day, cause osteoarthritis.After modeling the 14th day starts administration, and each group dosage is as follows: normal group and model group, give normal saline gavage 1mL/100g body weight; Glucosamine group, glucosamine 1g adds 500mL normal saline and becomes suspension, gives gavage 1mL/100g body weight: target compound group, and the target compound of 0.01g adds 5000mL normal saline and becomes suspension, gives gavage 1mL/100g body weight.1 times/day, successive administration 30d, draws materials for after modeling the 49th day.
ELISA method detects IgG2 α
The 49th day by sacrifice of animal after, row ventral aorta take a blood sample, by the centrifugal 5min of institute blood sampling 3000r/min, get serum, put-80 DEG C of Refrigerator stores to be measured.Concrete operation step is undertaken by test kit (IgG2 α ELISA kit is purchased from Mei Lian bio tech ltd, Shanghai) description.The results are shown in following table.
| Group | IgG2α(μg·mL -1) |
| Normal group | 42.61±4.38 |
| Model group | 56.81±5.06 |
| Glucosamine group | 48.19±4.16 |
| Target compound | 43.52±4.33 |
Claims (7)
1. treat a compound for joint disease, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for joint disease, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of joint disease according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
4. the pharmaceutical composition for the treatment of joint disease according to claim 3, is characterized in that, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of joint disease according to claim 4, is characterized in that, described diluent is lactose.
6. the pharmaceutical composition for the treatment of joint disease according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment joint disease, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510901800.5A CN105395553A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition for osteoarticular disease rehabilitation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510901800.5A CN105395553A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition for osteoarticular disease rehabilitation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105395553A true CN105395553A (en) | 2016-03-16 |
Family
ID=55461551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510901800.5A Pending CN105395553A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition for osteoarticular disease rehabilitation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105395553A (en) |
-
2015
- 2015-12-08 CN CN201510901800.5A patent/CN105395553A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU669903B2 (en) | Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic | |
| US9682099B2 (en) | Compositions and methods for treating joints | |
| US11433102B2 (en) | Compositions and methods for treating Parkinson's disease (PD) and related disorders | |
| CN107427546B (en) | Composition containing extract of discorea nipponica and its medicinal use | |
| US20210121538A1 (en) | Interactional Biosystem | |
| CN102459245B (en) | Thioxanthene derivatives for the treatment of infectious diseases | |
| CN105395553A (en) | Pharmaceutical composition for osteoarticular disease rehabilitation | |
| WO2020092650A1 (en) | Compositions and methods for modulating t cell exhaustion | |
| JP2015535225A (en) | Triazine derivatives for treating conditions related to nicotinamide adenine dinucleotide phosphate oxidase | |
| CN108853081B (en) | Application of amentoflavone in preparation of medicine for treating necrotic enteritis of chicken | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| KR102037996B1 (en) | A composition for preventing or treating of diabetes mellitus type2 comprising tonsil-derived mesenchymal stem cell or conditioned medium thereof | |
| CN105348171A (en) | Pharmaceutical composition for treating knee osteoarthritis | |
| TWI404542B (en) | Compositions of clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
| CN101690728B (en) | Composition for treating osteoarthritis | |
| CN104490893B (en) | A kind of pharmaceutical composition of Cure for insomnia | |
| US20220047663A1 (en) | Formulation for inhibiting virus replication | |
| CN114642682B (en) | Application of two-dimensional nanomaterial in inhibiting coronavirus | |
| CN109550041B (en) | Application of oritavancin phosphate in preparation of medicine for preventing and treating infectious bovine rhinotracheitis | |
| CN105541838A (en) | Medicine composition for treating kidney stones | |
| CN105367511A (en) | Pharmaceutical composition used for treating bone diseases | |
| US20180289745A1 (en) | Compositions and Methods for Treating Parkinson's Disease (PD) and Related Disorders | |
| CN105796564B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| WO2015084706A1 (en) | Intra-articular formulations and methods for treatment of osteoarthritis | |
| CN104922102B (en) | Soviet Union's shepherd's purse ramie flavones is preparing the application in anti-anoxic medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160316 |
|
| WD01 | Invention patent application deemed withdrawn after publication |